NSEAnalysts/Institutional Investor Meet/Con. Call Updates1d ago · 21 Jul 2026, 04:19 pm

Analysts/Institutional Investor Meet/Con. Call Updates

Senores Pharmaceuticals Limited · SENORES

✦ AI SummaryResults

Senores Pharmaceuticals Limited has scheduled an earnings conference call for Q1FY27 on July 27, 2026, following the announcement of unaudited consolidated and standalone financial results for the quarter ended June 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Senores Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for Q1FY27 scheduled to be held on July 27, 2026 at 05:15 P.M. (IST)

Attachments (1)

📄

SENORES_21072026161904_Reg_30_earningscall_SPL_final_signed.pdf

pdf

Download →
View document text
Date: July 21, 2026 To, To, Sr. General Manager Sr. General Manager BSE Limited National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES DSuebar.: SIinrt/iMmaadtaiomn, for Earnings Conference Call for Q1FY27 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that, post announcement of Unaudited Consolidated and Standalone Financial Results for the quarter ended June 30, 2026, the Company will hold the earnings conference call for Q1FY27 on Monday, July 27, 2026 at 05:15 P.M. (IST). The details of the aforesaid earnings conference call are annexed herewith. The audio recording and transcript of the aforesaid call will be subsequently published on the website of the Company and will be intimated accordingly. You are requested to take the same on record. TFohra nSkeinnogr yeosu P. harmaceuticals Limited Deval Rajnikant Shah Whole-Time Director & CFO DIN: 00332722 Enclosures: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Senores Pharmaceuticals Ltd Q1FY27 Earnings Call Monday, 27 July 2026 at 17:15 hrs (IST) DAM Capital Advisors Ltd invites you to Senores Pharmaceuticals Ltd’s post results conference call Senores Pharmaceuticals Ltd’s Management Speakers Mr. Swapnil Shah – Promoter and Managing Director Mr. Sanjay Majmudar – Chairman Mr. Deval Shah – Whole Time Director and Chief Financial Officer Call Leaders Nitin Agarwal – Analyst, DAM Capital Advisors Ltd Dial-in Details Universal access: +91 22 6280 1384, +91 22 7115 8285 (accessible from all networks and countries) Diamond passcode link: click here International timings Hong Kong Singapore UK USA 19:45 (HKT) 19:45 (SGT) 12:45 (BST) 07:45 (EDT) Toll free 800964448 8001012045 08081011573 18667462133 *Please dial-in at least 5-10 minutes prior to the schedule to get connected to the call in time For further information please contact Nitin Agarwal / Payal Shah DAM Capital Advisors Limited : +91 22 4202 2568 / 2638  nitin.a@damcapital.in / payal@damcapital.in